🇺🇸 FDA
Pipeline program

Dexmedetomidine

30561

Approved small_molecule active

Quick answer

Dexmedetomidine for Schizophrenia Agitation is a Approved program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
BioXcel Therapeutics
Indication
Schizophrenia Agitation
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials